Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Jun 9;12:786981. doi: 10.3389/fonc.2022.786981

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Wang, Wei, Hu, Pan, Wu, Wang, Zhang, Shi, Liu, Zhao, Zhu and Ye

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The study design, inclusion criteria, and participants. (A) The validation cohorts were composed by patients from the FUSCC database (FAI cohort A) and TCGA/TCIA database (FAI cohort B). We excluded patients who did not have CT scans and those who had extreme values of VFA. The final included patients were 129 from the FUSCC cohort and 218 from the TCGA/TCIA cohort. (B) The imaging genomics cohort prospectively included consecutive unselected patients from FUSCC who had nephrectomy or nephron sparing surgery. After excluding 8 patients who were not clear cell RCC and 2 patients with unqualified tissue samples, the final cohort included 19 patients. (C) The treatment response cohort included patients from a FUSCC cytoreductive surgery database. All patients had CT scans of the kidney tumor before and after two months of neoadjuvant/palliative targeted therapy, and then they undergone nephrectomies.